NATCOPHARM.NS NATCO Pharma Ltd.
Price history
Price is the daily close from stored Kite history. The other metrics pair that daily price with the company's periodic filings — each fundamental (revenue, EPS, equity…) is held flat at its latest filed value between annual filings, so a ratio steps at each filing and moves daily only through its price term. A metric with no input on file for this company (e.g. EV/EBITDA for a bank, which has no EBIT) is shown as unavailable, never guessed. Share-count-based metrics use the latest diluted share count against split/bonus-adjusted prices.
Technical indicators
ℹ These reflect only the stock's recent price and volume behavior — not the company's fundamentals — and are not a recommendation to buy or sell. Standard published parameters are used throughout (see each chart's own label); a company with too little stored price history for a given indicator's lookback window shows that plainly below rather than a garbage or misleading value.
MACD (12,26,9), Stochastic Oscillator (14,3) and Money Flow Index (14-day) each carry their own published reference lines/bands (20/80 for the oscillator readings) where one is standard. ADX includes +DI/-DI for direction alongside trend strength; a dashed line marks the commonly published 25 "trending market" reading. ATR is shown in raw rupees here; the price/volume preset screen (below, and on the Screener page) reports it as a % of price so it's comparable across stocks at different price levels. Computed from the same stored daily OHLCV history as the price chart above — no new data source.
Delivery volume
| Date | Traded Qty | Delivery Qty | Delivery % |
|---|---|---|---|
| 2026-08-28 | 402204 | 230311 | 57.26% |
| 2026-08-27 | 279220 | 139700 | 50.03% |
| 2026-08-26 | 371204 | 172898 | 46.58% |
| 2026-08-25 | 443465 | 267225 | 60.26% |
| 2026-08-24 | 317429 | 129450 | 40.78% |
| 2026-08-21 | 363713 | 126904 | 34.89% |
| 2026-08-20 | 275997 | 135323 | 49.03% |
| 2026-08-19 | 318070 | 140000 | 44.02% |
| 2026-08-18 | 281134 | 119000 | 42.33% |
| 2026-08-17 | 844481 | 322693 | 38.21% |
| 2026-08-14 | 2494304 | 424918 | 17.04% |
| 2026-08-13 | 1200054 | 446269 | 37.19% |
| 2026-08-12 | 270111 | 144356 | 53.44% |
| 2026-08-11 | 406109 | 165674 | 40.80% |
| 2026-08-10 | 199069 | 94613 | 47.53% |
| 2026-08-07 | 168655 | 81260 | 48.18% |
| 2026-08-06 | 209740 | 101581 | 48.43% |
| 2026-08-05 | 240030 | 102736 | 42.80% |
| 2026-08-04 | 315967 | 167100 | 52.89% |
| 2026-08-03 | 289116 | 154461 | 53.43% |
Delivery quantity/percentage from the NSE bhavcopy (DELIV_QTY/DELIV_PER) — the share of that day's traded volume that actually settled into a demat account, rather than being squared off intraday. A higher delivery percentage is commonly read as genuine accumulation/distribution rather than speculative same-day trading; this describes recent trading PATTERN, not the company itself, and is not a recommendation to buy or sell. A blank cell is a day NSE itself published no figure for, never a zero. Run python manage.py refresh_delivery_volumes --tickers NATCOPHARM.NS to fetch more history.
Insider trading activity
| Disclosed | Person | Category | Type | Mode | Quantity | Value (₹) | Resulting stake | |
|---|---|---|---|---|---|---|---|---|
| 11 Mar 2026 | SATYA VANI NANNAPANENI | Promoter Group | Sell | Market Sale | 45000 | 45059895 | 0.19% | XBRL |
| 11 Mar 2026 | SANJAY NANNAPANENI | Promoter Group | Sell | Market Sale | 70000 | 71211373 | 0.09% | XBRL |
| 01 Oct 2025 | SANJAY NANNAPANENI | Promoter Group | Sell | Market Sale | 100000 | 80305214 | 0.13% | XBRL |
| 17 Sep 2025 | SATYA VANI NANNAPANENI | Promoter Group | Sell | Market Sale | 23000 | 19720002 | 0.21% | XBRL |
| 11 Sep 2025 | SATYA VANI NANNAPANENI | Promoter Group | Sell | Market Sale | 17149 | 14519670 | 0.22% | XBRL |
| 12 Jun 2025 | PRAGNYA RAO DONTHINENI | Other | Buy | Market Purchase | 100 | 86500 | 0.00% | XBRL |
| 27 Mar 2025 | SANJAY NANNAPANENI | Promoter Group | Buy | Off Market | 286910 | 0 | 0.18% | XBRL |
| 21 Mar 2025 | VENKATA SATYA SWATHI KANTAMANI | Promoter Group | Sell | Off Market | 50000 | 0 | 8.90% | XBRL |
| 21 Mar 2025 | RAJEEV NANNAPANENI | Promoters | Sell | Off Market | 50000 | 0 | 0.60% | XBRL |
| 03 Mar 2025 | SATYA VANI NANNAPANENI | Promoter Group | Buy | Others | 420000 | 0 | 0.23% | XBRL |
| 03 Mar 2025 | SANJAY NANNAPANENI | Promoter Group | Buy | Others | 40000 | 0 | 0.02% | XBRL |
| 31 Dec 2024 | TUMMALA VENKAT RAO | Employees/Designated Employees | Sell | Market Sale | 2500 | 3450942 | 0.03% | XBRL |
| 31 Dec 2024 | Lakshminarayana Bolisetty | Director | Sell | Market Sale | 2000 | 2783220 | 0.00% | XBRL |
| 21 Dec 2024 | SADA SIVA RAO. NANNAPANENI | Employees/Designated Employees | Sell | Market Sale | 5000 | 7336084 | 0.04% | XBRL |
| 02 Dec 2024 | TUMMALA RAHUL | Other | Sell | Market Sale | 1000 | 1352855 | 0.00% | XBRL |
| 28 Nov 2024 | TUMMALA RAHUL | Other | Sell | Market Sale | 900 | 1223319 | 0.00% | XBRL |
| 12 Sep 2024 | AMIT SOGANI | - | Sell | Market Sale | 1500 | 2426355 | 0.00% | XBRL |
| 06 Sep 2024 | SUNIL KOTARU | - | Sell | Market Sale | 1310 | 2039178 | 0.00% | XBRL |
| 05 Sep 2024 | G VENKATA RAMANA | - | Sell | Market Sale | 2000 | 3066041 | 0.00% | XBRL |
| 02 Sep 2024 | M SUBBA RAO | - | Sell | Market Sale | 20000 | 30279976 | 0.02% | XBRL |
SEBI PIT (Prohibition of Insider Trading) Regulation 7 disclosures — designated persons (promoters, directors, KMPs, and their immediate relatives) reporting their own dealing in the company's securities, as NSE publishes them. Distinct from the SAST (Regulation 29 substantial-acquisition) filings on the market-wide SAST activity page. Public record only — this is descriptive disclosure data, not a signal, and is not a recommendation to buy or sell. Run python manage.py refresh_insider_trades --tickers NATCOPHARM.NS to fetch more.
Extract this company (financials + ratios + citations): CSV · XLSX
Full statements: Profit & Loss · Balance Sheet · Cash Flow · Compare with 46 peers in Healthcare · Trace Score
Ratios
This is cash paid during the fiscal year, not a per-share rate declared for it (no such element exists in the filing data) — timing can straddle interim/final dividends across years, and pre-FY2020-21 figures may include the since-abolished Dividend Distribution Tax, reading higher than later years for that reason alone.
Growth & earnings trend
Revenue & Profit CAGR
Operating Margin Trend
ROCE Trajectory
Earnings Quality
No persistent gap detected
Net Profit CAGR 69.96% vs CFO CAGR 148.33% over 4.0y (2022-03-31 → 2026-03-31); most recent year: Net Profit -24.76% vs CFO +4.21%
Sector-Relative Percentile (Healthcare)
Quarterly trend
| Metric (to shareholders basis) | Q4 FY2023-24 | Q1 FY2024-25 | Q2 FY2024-25 | Q3 FY2024-25 | Q4 FY2024-25 | Q1 FY2025-26 | Q2 FY2025-26 | Q3 FY2025-26 | Q4 FY2025-26 | Q1 FY2026-27 | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,068.30 Cr. | ₹1,362.60 Cr. | ₹1,371.10 Cr. | ₹474.80 Cr. | ₹1,221.00 Cr. | ₹1,328.90 Cr. | ₹1,363.00 Cr. | ₹647.30 Cr. | ₹739.10 Cr. | ₹735.20 Cr. | RevenueFromOperations |
| Net Profit | ₹386.30 Cr. | ₹668.50 Cr. | ₹677.30 Cr. incl. minority ₹676.50 Cr. | ₹133.00 Cr. incl. minority ₹132.40 Cr. | ₹406.60 Cr. incl. minority ₹406.00 Cr. | ₹480.70 Cr. incl. minority ₹480.30 Cr. | ₹518.40 Cr. incl. minority ₹517.90 Cr. | ₹151.50 Cr. incl. minority ₹151.30 Cr. | ₹267.90 Cr. incl. minority ₹269.00 Cr. | ₹206.50 Cr. | ProfitOrLossAttributableToOwnersOfParent |
Primary figures are Revenue from Operations and Net Profit attributable to shareholders — the basis the ratios use. Where they differ, the companion Gross revenue (incl. inter-segment) and incl. minority net profit (the totals a news headline usually quotes) are shown beneath, each traceable to its own XBRL element. Quarters shown are however many are actually stored (up to 10) — run python manage.py refresh_quarterly_trend --tickers NATCOPHARM.NS to fetch more.
Source document — income statement (FY2025-26, raw filing line items)
View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.
| ProfitOrLossAttributableToOwnersOfParent | 14185000000.0 |
| PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital | 179000000.0 |
Source document — balance sheet (FY2025-26, raw filing line items)
View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.
| CurrentAssets | 50523000000.0 |
| CurrentLiabilities | 16809000000.0 |
| EquityAttributableToOwnersOfParent | 92211000000.0 |
| BorrowingsCurrent + BorrowingsNoncurrent | 7064000000.0 |